文献速递胸部肿瘤放疗放疗物理与技术

质子束治疗高龄非小细胞肺癌的临床结果

Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2018-02-05

本研究回顾性评估质子束治疗80岁及以上非小细胞肺癌患者的疗效与安全性。提示质子束治疗对高龄非小细胞肺癌患者可行。

要点

  • 80岁及以上NSCLC患者接受质子束治疗,3年总生存率67.2%,3年局部控制率86.5%。
  • 仅2例发生2级肺炎,无3级及以上放射性肺炎,安全性可接受。
  • 2级肺炎与高肺V20、高平均肺剂量及低0.05 Gy(RBE)受照外肺体积比例显著相关(p=0.030)。

核心结论

  • 质子束治疗对80岁及以上非小细胞肺癌患者可行,可作为治疗选择之一。

研究设计与样本

  • 毒性评估采用不良事件通用术语标准4.0版。

主要发现

  • 中位质子束剂量80.0 Gy(RBE)(范围60.0-80.0 Gy [RBE]),所有患者均完成治疗。
  • 3年总生存率67.2%,其中可手术肺癌患者为90.0%,不可手术患者为58.2%;3年局部控制率86.5%。
  • 2例出现2级肺炎,无3级及以上放射性肺炎。
  • 2级肺炎发生率与高肺V20(p=0.030)、高平均肺剂量(p=0.030)及低0.05 Gy(RBE)受照外肺体积比例(p=0.030)显著相关。

临床怎么用

  • 对于80岁及以上非小细胞肺癌患者,质子束治疗可作为治疗选择之一。
  • 治疗计划中应关注肺V20和平均肺剂量,以降低2级肺炎风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of the present study was to evaluate retrospectively the efficacy and safety of proton beam therapy for elderly patients (≥80 years of age) with non-small cell lung cancer. METHODS: Patients diagnosed with T1-4 N0 M0 non-small cell lung cancer and treated with proton beam therapy between January 2009 and 2015 were recruited from our database retrospectively. Toxicity was evaluated using The Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Thirty-five patients, including 25 (71%) with clinically inoperable lung cancer, were administered proton beam therapy. The median age was 82 years (range: 80-87 years), and the median follow-up time was 34 months (range: 10-72 months). The median dose of proton beam therapy was 80.0 Gy relative biological effectiveness (RBE) (range: 60.0-80.0 Gy [RBE]), and all patients completed the treatments. All patients were followed for at least 23 months or until their death. The 3-year overall survival rate was 67.2% (90.0% in patients with operable lung cancer, and 58.2% in those with inoperable lung cancer). The 3-year local control rate was 86.5%. Two patients presented with grade 2 pneumonitis. The occurrence rate of grade 2 pneumonitis was significantly correlated with a high lung V20 (p = 0.030), and a high mean lung dose (p = 0.030), and a low ratio of lung volume spared from 0.05 Gy (RBE) dose (total lung volume minus lung volume irradiated at least 0.05 Gy [RBE]) (p = 0.030). However, there were no cases of grade 3 or higher radiation pneumonitis. CONCLUSIONS: This study suggests that the proton beam therapy was feasible for elderly patients with non-small cell lung cancer and can be considered as one of the treatment choices for elderly patients with lung cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ono T, Nakamura T, Yamaguchi H, et al. Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer. Radiat Oncol. 2018. PMID: 29402290. doi:10.1186/s13014-018-0967-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。